PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+1.52%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$887M
AUM Growth
+$887M
(-20%)
Cap. Flow
-$96M
Cap. Flow
% of AUM
-10.82%
Top 10 Holdings %
Top 10 Hldgs %
73.36%
Holding
40
New
6
Increased
12
Reduced
9
Closed
2
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$11.6M |
| 2 |
ELEV
Elevation Oncology
ELEV
|
$6.91M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$4.23M |
| 4 |
Nuvation Bio
NUVB
|
$2.81M |
| 5 |
AnaptysBio
ANAB
|
$2.55M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$32M |
| 2 |
Insmed
INSM
|
$29.5M |
| 3 |
United Therapeutics
UTHR
|
$29.4M |
| 4 |
Biogen
BIIB
|
$19.5M |
| 5 |
Amicus Therapeutics
FOLD
|
$12.1M |
Sector Composition
| 1 | Healthcare | 98.15% |
| 2 | Financials | 1.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $120M | 13.53% | 4,423,369 -1,088,352 | -20% | -$29.5M |
|
|
2
Amicus Therapeutics
FOLD
$2.34B
| $110M | 12.41% | 9,344,102 -1,029,613 | -10% | -$12.1M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $99.1M | 11.18% | 1,134,569 -366,180 | -24% | -$32M |
|
|
4
Biogen
BIIB
$19.4B
| $62.5M | 7.05% | 289,958 -90,459 | -24% | -$19.5M |
|
|
5
United Therapeutics
UTHR
$13.8B
| $61.5M | 6.94% | 267,759 -128,025 | -32% | -$29.4M |
|
6
STAAR Surgical
STAA
$1.36B
| $52.8M | 5.96% | 1,379,590 +2,640 | +0.2% | +$101K |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $44.7M | 5.04% | 2,414,943 +5,387 | +0.2% | +$99.6K |
|
8
Prothena Corp
PRTA
$441M
| $41.2M | 4.65% | 1,663,448 +3,391 | +0.2% | +$84K |
|
9
Iovance Biotherapeutics
IOVA
$807M
| $31.3M | 3.53% | 2,112,811 +6,019 | +0.3% | +$89.2K |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $27.3M | 3.08% | 182,766 +28,329 | +18% | +$4.23M |
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $26.1M | 2.94% | 201,265 +360 | +0.2% | +$46.6K |
|
|
RVNC
12
DELISTED
Revance Therapeutics, Inc.
RVNC
| $25.8M | 2.91% | 5,248,004 +10,720 | +0.2% | +$52.7K |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $18.8M | 2.13% | 1,005,776 +14,251 | +1% | +$267K |
|
|
14
AnaptysBio
ANAB
$569M
| $18M | 2.03% | 799,906 +113,024 | +16% | +$2.55M |
|
15
eHealth
EHTH
$118M
| $16.4M | 1.85% | 2,715,681 -23,698 | -0.9% | -$143K |
|
16
Align Technology
ALGN
$10.3B
| $16.1M | 1.82% | 49,105 -6,600 | -12% | -$2.16M |
|
17
Alkermes
ALKS
$4.78B
| $13.4M | 1.51% | 495,592 -107,808 | -18% | -$2.92M |
|
|
SLRN
18
DELISTED
ACELYRIN
SLRN
| $11.6M | 1.31% | +1,715,180 | New | +$11.6M |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $10.8M | 1.22% | 750,371 | – | – |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $9.64M | 1.09% | 405,193 -67,407 | -14% | -$1.6M |
|
21
NovoCure
NVCR
$1.38B
| $8.78M | 0.99% | 561,908 | – | – |
|
22
Cytokinetics
CYTK
$4.23B
| $7.83M | 0.88% | 111,717 | – | – |
|
23
Karyopharm Therapeutics
KPTI
$61.7M
| $7.7M | 0.87% | 5,102,193 | – | – |
|
|
VERV
24
DELISTED
Verve Therapeutics
VERV
| $7.65M | 0.86% | 575,817 | – | – |
|
25
Gossamer Bio
GOSS
$562M
| $7.54M | 0.85% | 6,391,775 +432,887 | +7% | +$511K |
|